Hikma signs exclusive licensing, distribution and supply agreement with Basilea for Cresemba

Cresemba (isavuconazole) is an injectable and oral anti-fungal product.

Under the terms of the amended agreement, Hikma will have the exclusive rights to register, distribute and market Cresemba in all its MENA markets leveraging Hikma’s strong local presence, sales and marketing capabilities and regulatory expertise.

Cresemba has received approvals across Europe and the US. In March 2015, the product was approved by the FDA for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis. The European marketing authorisation was granted in October 2015 to isavuconazole for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate.

Mazen Darwazah, Vice Chairman and CEO of MENA and Emerging Markets said: “We are delighted to be building on our partnership with Basilea enabling us to continue enhancing our growing portfolio of high value products in the MENA and reinforcing our commitment to increasing patients’ access to high-quality medicines.”